Nature of the Regulatory Record

The FDA's ANDA 204681 page is a database entry for generic nitroglycerin approval data. An Abbreviated New Drug Application (ANDA) is an approval pathway that assesses bioequivalence, quality, and manufacturing capability against a reference listed drug, rather than requiring new clinical trials. Therefore, this record should be interpreted as insight into the regulatory and competitive landscape of the established angina treatment market, not as an announcement of new clinical efficacy.

Drug and Clinical Positioning

The reference brand is Nitrostat (Viatris [VTRS]), with nitroglycerin as the active ingredient. Its target is not a single receptor but the nitric oxide (NO)-soluble guanylate cyclase (sGC)-cGMP pathway. It works by relaxing vascular smooth muscle, reducing preload and myocardial oxygen demand, and is used for the relief and prevention of acute angina attacks due to coronary artery disease. Sublingual tablets are available in 0.3 mg, 0.4 mg, and 0.6 mg strengths and are in the marketed phase, not development. Co-administration with phosphodiesterase-5 inhibitors poses a risk of severe hypotension, making prescription safety a key concern.

Approval History and Competitive Landscape

Nitrostat received its initial US approval in 1981. The current reference NDA 021134 products (0.3 mg, 0.4 mg, and 0.6 mg) were approved on May 1, 2000. This generic approval pathway did not involve a vote by the FDA's New Drug Advisory Committee. The FDA approved Dr. Reddy's Laboratories' (RDY) identical strength sublingual tablets on August 26, 2016, followed by products from Glenmark Pharmaceuticals, Natco Pharma, Rubicon Research, Aurobindo Pharma, Mankind Pharma, and Viwit Pharmaceutical. Direct competitors are AB-rated sublingual tablets, with alternative formulations including Nitrolingual pump spray and GoNitro sublingual powder serving as differentiators based on price and supply stability.

Market and Investment Interpretation

The US Nitrostat market was valued at approximately USD 70 million in 2022, according to third-party estimates. In this mature market with multiple AB-rated generics, a single approval is unlikely to drive high-growth revenue; instead, insurance coverage, wholesale distribution, and manufacturing costs determine market share. For patients, diversification of supply sources and price competition for this essential emergency medication for acute chest pain are significant. From a corporate valuation perspective, key indicators are production reliability, recall history, actual launch status, and prescription volume rather than patent exclusivity.